Annovis Bio (ANVS) Change in Accured Expenses (2019 - 2026)

Annovis Bio has reported Change in Accured Expenses for 8 years, with the latest figure at $6.5 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 1567.69% year-over-year to $6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (up 1619.92% YoY) and the FY2025 annual result came in at -$530154.0, up 62.43% from the prior year.
• Change in Accured Expenses climbed to $6.5 million in Q1 2026 per ANVS's latest filing, from -$576912.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $6.5 million in Q1 2026 and troughed at -$2.5 million in Q1 2023.
• A 5-year average of $393913.9 and a median of -$70581.0 in 2022 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 24711.12% in 2022, down 2022.74% in 2022.
• Over 5 years, Change in Accured Expenses stood at $3.1 million in 2022, then sank by 55.9% to $1.3 million in 2023, then slumped by 79.0% to $283051.0 in 2024, then slumped by 303.82% to -$576912.0 in 2025, then surged by 1221.51% to $6.5 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $6.5 million, -$576912.0, and -$209042.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.